financetom
Business
financetom
/
Business
/
Siachen now open for tourism
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Siachen now open for tourism
Oct 21, 2019 8:07 AM

The Siachen Glacier in India, which is the world's highest battlefield, has now been opened to tourists, Defence Minister Rajnath Singh said in Ladakh on Monday.

The Defence Minister was in Ladakh, along with Army chief Gen. Bipin Rawat, to inaugurate a strategically located bridge across the Shyok River which will provide easy connectivity with the Daulat Beg Oldi sector along the Line of Actual Control (LAC) with China.

"Ladakh has tremendous potential in tourism. Better connectivity in Ladakh would certainly bring tourists in large numbers. The Siachen area is now open for tourists and tourism. From Siachen Base Camp to Kumar Post, the entire area has been opened for tourism purposes," Rajnath Singh said in a tweet.

The Indian Army had been allowing expeditions to Siachen in the late 1970s till they came to a total stop in 1984.

The announcement regarding the opening up of Siachen for tourists comes a few days ahead of Ladakh being declared a separate Union Territory on October 31.

In June this year, Rajnath Singh, accompanied by Gen. Rawat, had visited Siachen and praised the "tenacious resolve and unstinting commitment" of the soldiers deployed in the region. He had undertaken an aerial reconnaissance of the Siachen Glacier and interacted with troops at one of the forward posts.

First Published:Oct 21, 2019 5:07 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amneal Pharmaceuticals' Crexont Added to Three Insurance Coverage Accounts
Amneal Pharmaceuticals' Crexont Added to Three Insurance Coverage Accounts
Apr 3, 2025
10:02 AM EDT, 04/03/2025 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) said Thursday that the Veterans Administration, UnitedHealthcare (UNH), and CVS Health ( CVS ) have added Parkinson's disease treatment Crexont to their national prescription drug formularies. The company said the additional coverage increases the total US insurance coverage of Crexont to more than 50% of covered patients from...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Jewellery maker Pandora sees annual impact from US tariffs of $178 mln
Jewellery maker Pandora sees annual impact from US tariffs of $178 mln
Apr 3, 2025
COPENHAGEN, April 3 (Reuters) - Danish jewellery maker Pandora said on Thursday it estimates the total impact of U.S. tariffs on the company to be around 1.2 billion crowns ($178.34 million) per year, with the impact in 2025 to be around 700 million crowns. ($1 = 6.7288 Danish crowns) ...
Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment
Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment
Apr 3, 2025
10:01 AM EDT, 04/03/2025 (MT Newswires) -- Akebia Therapeutics ( AKBA ) said Thursday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Xoanacyl for treating elevated serum phosphorus and iron deficiency in adults with chronic kidney disease. The company said Averoa, a biopharmaceutical company specializing in renal treatments, licensed the rights from Akebia...
Copyright 2023-2026 - www.financetom.com All Rights Reserved